{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "BRAF inhibitor",
      "Melanoma",
      "dabrafenib",
      "pyrexia",
      "trametinib"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "24664475",
  "DateCompleted": {
    "Year": "2016",
    "Month": "04",
    "Day": "04"
  },
  "DateRevised": {
    "Year": "2018",
    "Month": "12",
    "Day": "03"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2014",
        "Month": "03",
        "Day": "24"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1177/1078155214527859"
    ],
    "Journal": {
      "ISSN": "1477-092X",
      "JournalIssue": {
        "Volume": "21",
        "Issue": "4",
        "PubDate": {
          "Year": "2015",
          "Month": "Aug"
        }
      },
      "Title": "Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners",
      "ISOAbbreviation": "J Oncol Pharm Pract"
    },
    "ArticleTitle": "Facing the challenges of new melanoma-targeted therapies: Treatment of severe fevers associated with dabrafenib/trametinib combination therapy.",
    "Pagination": {
      "StartPage": "293",
      "EndPage": "295",
      "MedlinePgn": "293-5"
    },
    "Abstract": {
      "AbstractText": [
        "With the emergence of new oral therapies for metastatic melanoma to the market, as well as ongoing pre-marketing trials and special access schemes, it is important to keep up to date with the side effect profiles of these medications. A common side effect associated with the BRAF inhibitor dabrafenib is severe fever symptoms such as pyrexia and rigors/chills; however, treatment options are limited. We report a patient who was debilitated by severe pyrexia and rigors caused by dabrafenib used in combination with trametinib to treat metastatic melanoma, who was treated with low-dose steroids. To our knowledge, the use of prednisolone for the treatment and prevention of further dabrafenib-associated pyrexia is not published; however, it is a low risk and low cost option that was very effective in this case."
      ],
      "CopyrightInformation": "\u00a9 The Author(s) 2014."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Royal North Shore Hospital, Sydney, Australia julianlindsay1@gmail.com."
          }
        ],
        "LastName": "Lindsay",
        "ForeName": "Julian N",
        "Initials": "JN"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia."
          }
        ],
        "LastName": "Barras",
        "ForeName": "Michael",
        "Initials": "M"
      }
    ],
    "PublicationTypeList": [
      "Case Reports",
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "J Oncol Pharm Pract",
    "NlmUniqueID": "9511372",
    "ISSNLinking": "1078-1552"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Cephalosporins"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Imidazoles"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Oximes"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Pyridones"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Pyrimidinones"
    },
    {
      "RegistryNumber": "33E86K87QN",
      "NameOfSubstance": "trametinib"
    },
    {
      "RegistryNumber": "807PW4VQE3",
      "NameOfSubstance": "Cefepime"
    },
    {
      "RegistryNumber": "QGP4HA4G1B",
      "NameOfSubstance": "dabrafenib"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects"
      ],
      "DescriptorName": "Antineoplastic Combined Chemotherapy Protocols"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cefepime"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Cephalosporins"
    },
    {
      "QualifierName": [
        "adverse effects"
      ],
      "DescriptorName": "Drug Delivery Systems"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [
        "chemically induced",
        "diagnosis",
        "drug therapy"
      ],
      "DescriptorName": "Fever"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects"
      ],
      "DescriptorName": "Imidazoles"
    },
    {
      "QualifierName": [
        "diagnosis",
        "drug therapy"
      ],
      "DescriptorName": "Melanoma"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects"
      ],
      "DescriptorName": "Oximes"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects"
      ],
      "DescriptorName": "Pyridones"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects"
      ],
      "DescriptorName": "Pyrimidinones"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Severity of Illness Index"
    }
  ]
}